Cargando…
Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia
TCF3-PBX1 (E2A-PBX1) is a recurrent gene fusion in B-cell precursor acute lymphoblastic leukemia (BCP-ALL), which is caused by the translocation t(1;19)(q23;p13). TCF3-PBX1 BCP-ALL patients typically benefit from chemotherapy; however, many relapse and subsequently develop resistant disease with few...
Autores principales: | Eldfors, S, Kuusanmäki, H, Kontro, M, Majumder, M M, Parsons, A, Edgren, H, Pemovska, T, Kallioniemi, O, Wennerberg, K, Gökbuget, N, Burmeister, T, Porkka, K, Heckman, C A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220125/ https://www.ncbi.nlm.nih.gov/pubmed/27461063 http://dx.doi.org/10.1038/leu.2016.202 |
Ejemplares similares
-
Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML
por: Malani, D, et al.
Publicado: (2017) -
Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing
por: Pietarinen, P O, et al.
Publicado: (2015) -
Molecular characterization of TCF3::PBX1 chromosomal breakpoints in acute lymphoblastic leukemia and their use for measurable residual disease assessment
por: Burmeister, Thomas, et al.
Publicado: (2023) -
Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies
por: Yadav, Bhagwan, et al.
Publicado: (2014) -
Genetic features of B‐cell lymphoblastic lymphoma with
TCF3‐PBX1
por: Shirai, Ryota, et al.
Publicado: (2021)